The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Premier Miton sizes up Tellworth Investments

Wed, 01st Nov 2023 16:54

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Premier Miton Group PLC - Surrey, England-based asset manager - Acquires equity boutique Tellworth Investments LLP. Tellworth has GBP559 million of assets under management as of end of September. "The acquisition is in line with Premier Miton's stated inorganic strategy of buying complimentary asset management platforms with industry expertise and product diversification as part of a wider commitment to continue to invest in growth opportunities," Premier Miton says. Says initial consideration based on assets under management at completion. "At the current AuM this will be GBP5.5 million but this can vary between GBP3.5 million and GBP6 million depending on AuM at completion," it adds. Initial consideration to be 75% paid for in cash and 25% in shares. Premier Miton adds: "An additional consideration of up to GBP3 million may be payable depending on AuM growth between completion and the first anniversary of completion with the maximum amount payable if AuM at the first anniversary date exceeds GBP850 million."

----------

Reconstruction Capital II Ltd - closed-end investment company - Sends circular to shareholders concerning proposal to cancel AIM admission. "The directors have conducted a review of the benefits and drawbacks to the company and its shareholders in retaining its admission to trading on AIM and believe that cancellation is in the best interests of the company and its shareholders as a whole," it says. It believes AIM listing comes with "considerable cost" and mean it is unlikely to "provide the company with significantly wider access to capital". It backs its continuation, however, adding: "The directors have concluded that given the slow process of selling the investments, exacerbated by the Covid-19 crisis followed by the war in Ukraine and resulting cost of living crisis, which has had a significant impact on the main investee company Policolor and on Mamaia Resort Hotels, it is in the best interests of the company to further extend its life." Shareholders will vote on AIM cancellation proposal at November 29 annual general meeting.

----------

Highbridge Tactical Credit Fund Ltd - credit investment fund - Says compulsorily redeemed majority of shares and resolutions to take company into voluntary liquidation passed. Shares suspended on Wednesday, with delisting expected on Thursday.

----------

Asian Energy Impact Trust PLC - investment company focused on sustainable energy infrastructure projects - Enters agreement which will see Octopus Energy Generation act as its transitional investment manager. Asian Energy Impact says: "Octopus Energy Generation's immediate priorities will be to assist finalising the 31 December 2022 and 30 June 2023 valuations, 2022 audit and accounts and 2023 interim report and lifting the suspension of admission to listing and trading of the company's shares as soon as possible. This process will include undertaking detailed due diligence on the company's assets, including the in-construction 200 MW DC solar PV project in Rewa Ultra Mega solar park, to ensure the completeness and accuracy of all information required to finalise the outstanding valuations, audit and financial reports."

----------

Zephyr Energy PLC - Rocky Mountains-focused oil and gas company - Says Slawson Exploration Co operated wells, which Zephyr has working interest in, come online on Wednesday. "The wells will provide a significant near-term production boost and are expected to generate substantial cashflows for the company which can be reinvested into the development of its project in the Paradox Basin, Utah, US or into additional non-operated investment opportunities," Zephyr adds.

----------

Zenith Energy Ltd - Africa and Italy-focused oil and gas company - Begins International Chamber of Commerce arbitration case against Tunisia's national oil company, Entreprise Tunisienne d'Activites Petrolieres. Chief Executive Officer Andrea Cattaneo says: "It is deeply regrettable that Zenith Energy has been compelled to initiate a second arbitration and conduct conservative seizures against ETAP following failures to satisfy contractually binding payments for oil production. Shareholders can take comfort in the decisive action the board has taken to ensure that Zenith's interests are upheld."

----------

MGC Pharmaceuticals Ltd - pharmaceutical company specialising in plant-derived medicines - Receives binding commitments from "sophisticated and professional investors" to subscribe for USD7.9 million shares under a placement at USD0.255 each. Follows shareholder approval of new share placement. "The USD7.9 million secured represents the minimum amount required to fund MGC Pharma's full business plan over the next 12-month period, that is focused on the investigational new drug applications of CimetrA and CannEpil in the USA," MGC says. Adds that following completion of share consolidation, predicted to occur on Thursday, will have 4.4 million shares in issue.

----------

Equals Group PLC - London-based fintech payments group - Says capital reduction approved by UK court, resulting in distributable reserves of around GBP25 million. Plans to declare maiden interim dividend of 0.5 pence per share. It adds: "Furthermore, it expects that, subject to shareholder approval, the final dividend for the 2023 full year will be 1.0 pence per share, giving a total dividend of 1.5 pence for 2023."

----------

Chelverton Growth Trust PLC - invests in mid- to small-cap UK companies - Recommends members' voluntary liquidation of company. It explains: "The board has concluded that the reduced size of the company and its small number of investments preclude a further tender offer, and as reported in the company's annual report and accounts, it has for some time been investigating other options to maximise the return of funds to shareholders. Unfortunately, this process has been necessarily drawn out due to major economic events including Brexit, Covid-19 and the Russian invasion of Ukraine. These events have served to create market uncertainty and turmoil such that only in recent months has the board felt able to move forward with its plans within a more stable economic environment." Believes wind-up is in best interests of shareholders. Plans initial distribution of shares in AIM-listed industrial holding company CEPS PLC once liquidation proposal backed. General meeting which will include vote on proposal takes place on November 27.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.